scholarly journals Mutation prevalence tables for hereditary cancer derived from multigene panel testing

2020 ◽  
Vol 41 (8) ◽  
Author(s):  
Steven N. Hart ◽  
Eric C. Polley ◽  
Amal Yussuf ◽  
Siddhartha Yadav ◽  
David E. Goldgar ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Multigene Panel Testing for Hereditary Cancer Risk

2016 ◽  
Vol 7 (4) ◽  
Author(s):  
Alyssa A. Grissom, MSN, APN, AGCNS, OCN ◽  
Patricia J. Friend, PhD, APN-CNS, AOCNS, AGN-BC
Keyword(s):  
Cancer Risk ◽  
Hereditary Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

scholarly journals Multigene panel testing for breast cancer patients at high risk for hereditary cancer

2016 ◽  
Vol 27 ◽  
pp. vi465
Author(s):  
H.-C. Shin ◽  
T.-K. Yoo ◽  
E. Lee ◽  
H.-B. Kee ◽  
J. Han ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Hereditary Cancer ◽  
Breast Cancer Patients ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Are we still adjusting to multigene panel testing? An NCI-designated cancer center's 2-year experience.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1585-1585
Author(s):  
Chethan Ramamurthy ◽  
Mark A. Hitrik ◽  
Lyudmila DeMora ◽  
Andrea Forman ◽  
Kim Rainey ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Hereditary Cancer ◽  
Cancer Center ◽  
Genetic Tests ◽  
Detection Rates ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Disease Specific ◽  
Over Time ◽  
Multigene Panel

1585 Background: Genetic testing for hereditary cancer predisposition has rapidly changed over the past few years with the introduction of multigene panel testing. Multigene testing has evolved from disease-agnostic comprehensive (C) panels alone to include disease-specific but expanded (DSE) panels as well as guideline-based (GB) panels. We analyzed trends in utilization of genetic testing over a two-year period in one NCI-designated Cancer Center, hypothesizing that over time genetic testing usage would trend toward more disease-specific panels. Methods: We conducted a retrospective analysis of our program’s database for all germline genetic tests ordered from 9/1/2013 to 8/31/2015 (n = 619; 246 in year 1, and 373 in year 2). Tests were categorized into three groups based on specificity: GB (range: 2-12 genes tested), DSE (12-35 genes tested), and C (28-80 genes tested). The Chi-square test was used to analyze test types ordered in year 1 (9/1/2013-8/31/2014) and year 2 (9/1/2014 – 8/31/2015) and the proportions of resulting mutation types. Results: A total of 604 germline genetic tests met the inclusion criteria: 39 GB (20 year 1, 19 year 2), 171 DSE (43 year 1, 128 year 2), and 394 C (180 year 1, 214 year 2). Compared to year 1, a larger proportion of DSE tests (35% v. 18%, p < 0.001), and a smaller proportion of C tests (59% v. 74%, p < 0.001) and GB tests (5% vs. 8%, p = 0.146) were ordered. DSE panels revealed a pathogenic variant (PV) at a rate of 16% and a variant of unknown significance (VUS) at a rate of 24%. C tests revealed a PV and VUS at rates of 14% and 29%, respectively. GB tests revealed a PV and VUS at rates of 21% and 18%, respectively. No statistically significant differences in detection rates of mutation types (PV or VUS) were found between GB, DSE, or C tests. Conclusions: The rates of PV detection were not significantly different between test types, but the profile of tests ordered changed over time to favor DSE panels. Exploration of factors contributing to changing trends in genetic testing are warranted as counselors and clinicians adapt to the quickly expanding number of genes associated with hereditary cancer risks, many of them moderate-risk, and the evolving landscape of multigene panel testing.

scholarly journals Adoption of multigene panel testing for hereditary cancer "CancerNext" in Tohoku University Hospital

2019 ◽  
Vol 30 ◽  
pp. vi99
Author(s):  
Keigo Komine ◽  
Masanobu Takahashi ◽  
Sakura Hiraide ◽  
Hideharu Yamada ◽  
Mari Tsubata ◽  
...  
Keyword(s):  
Hereditary Cancer ◽  
University Hospital ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights

2019 ◽  
Vol 28 (6) ◽  
pp. 1198-1207
Author(s):  
Lindsey Sawyer ◽  
Heather Creswick ◽  
Raymond Lewandowski ◽  
John Quillin
Keyword(s):  
Hereditary Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel
Sign in / Sign up

Export Citation Format

Share Document